Literature DB >> 34306333

RP11-874J12.4, a novel lncRNA, confers chemoresistance in human gastric cancer cells by sponging miR-3972 and upregulating SSR2 expression.

Yi Liu1, Jian Cao2, Yan-Song Pu3, Yu Ma4, Min Wu5, Jian-Hua Wang3.   

Abstract

Increasing evidence has revealed the contributions of long noncoding RNAs (lncRNAs) in the modulation of drug resistance in gastric cancer. In the present study, we explored the role of a novel lncRNA, RP11-874J12.4, in regulating chemoresistance in gastric cancer and determined the underlying molecular mechanisms. We observed that compared with normal controls, human gastric cancer tissues and cell lines, including MKN-45 and AGS cells, expressed higher RP11-874J12.4 levels. RP11-874J12.4 knockdown sensitized MKN-45 and AGS cells to docetaxel and cisplatin in terms of cell viability and apoptosis rate. In addition, RP11-874J12.4 was found to be a competing endogenous RNA that sponged microRNA (miR)-3972, which showed significantly reduced expression in human gastric cancer tissues and cell lines. Furthermore, signal sequence receptor subunit 2 (SSR2) was identified as a downstream target of miR-3972, and the miR-3972/SSR2 axis was found to regulate chemoresistance in MKN-45 and AGS cells. SSR2 downregulation further sensitized gastric cancer cells with RP11-874J12.4 knockdown to chemotherapeutic drugs via enhanced apoptosis, which was evidenced by significantly upregulated expressions of cleaved caspase-3, cleaved caspase-9, and Bax and downregulated expression of Bcl-2. Furthermore, RP11-874J12.4 knockdown markedly inhibited the growth of xenograft MKN-45 cells in nude mice, which was associated with an increased expression of miR-3972 and decreased expression of SSR2 in tumors. Therefore, the RP11-874J12.4/miR-3972/SSR2 axis plays important roles in the regulation of chemoresistance in MKN-45 and AGS cells and may serve as a target for the diagnosis and treatment of human gastric cancer. AJTR
Copyright © 2021.

Entities:  

Keywords:  Long noncoding RNA; RP11-874J12.4; SSR2; chemoresistance; gastric cancer; miR-3972

Year:  2021        PMID: 34306333      PMCID: PMC8290636     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  40 in total

1.  Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.

Authors:  Chuanyao Cheng; Yaguang Qin; Qiongjie Zhi; Jianjun Wang; Changjiang Qin
Journal:  Int J Biol Macromol       Date:  2017-10-26       Impact factor: 6.953

2.  Liver extracellular matrix promotes BM-MSCs hepatic differentiation and reversal of liver fibrosis through activation of integrin pathway.

Authors:  Huanjing Bi; Leiguo Ming; Ruiping Cheng; Hailang Luo; Yongjie Zhang; Yan Jin
Journal:  J Tissue Eng Regen Med       Date:  2016-07-19       Impact factor: 3.963

Review 3.  MicroRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Hoell; Pavel Morozov; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 4.  The multilayered complexity of ceRNA crosstalk and competition.

Authors:  Yvonne Tay; John Rinn; Pier Paolo Pandolfi
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

5.  Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.

Authors:  M Saxena; M A Stephens; H Pathak; A Rangarajan
Journal:  Cell Death Dis       Date:  2011-07-07       Impact factor: 8.469

6.  PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers.

Authors:  Mohamad Moustafa Ali; Vijay Suresh Akhade; Subazini Thankaswamy Kosalai; Santhilal Subhash; Luisa Statello; Matthieu Meryet-Figuiere; Jonas Abrahamsson; Tanmoy Mondal; Chandrasekhar Kanduri
Journal:  Nat Commun       Date:  2018-02-28       Impact factor: 14.919

Review 7.  Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review).

Authors:  Chao Chen; Xiaohuan Tang; Yuanda Liu; Jiaming Zhu; Jingjing Liu
Journal:  Int J Oncol       Date:  2019-03-18       Impact factor: 5.650

Review 8.  Switching cell fate, ncRNAs coming to play.

Authors:  D Guan; W Zhang; W Zhang; G-H Liu; J C Izpisua Belmonte
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

9.  LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer.

Authors:  Yongfu Shao; Meng Ye; Qier Li; Weiliang Sun; Guoliang Ye; Xinjun Zhang; Yunben Yang; Bingxiu Xiao; Junming Guo
Journal:  Oncotarget       Date:  2016-06-21

Review 10.  Emerging role of long non-coding RNA in the development of gastric cancer.

Authors:  Hang Yu; Long Rong
Journal:  World J Gastrointest Oncol       Date:  2018-09-15
View more
  4 in total

1.  Clinical Value for Diagnosis and Prognosis of Signal Sequence Receptor 1 (SSR1) and Its Potential Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on High-Throughput Data Analysis.

Authors:  Liang Chen; Yunhua Lin; Guoqing Liu; Rubin Xu; Yiming Hu; Jiaheng Xie; Hongzhu Yu
Journal:  Int J Gen Med       Date:  2021-10-30

Review 2.  Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance.

Authors:  Ying Liu; Xiang Ao; Yu Wang; Xiaoge Li; Jianxun Wang
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

3.  Overexpression of SSR2 promotes proliferation of liver cancer cells and predicts prognosis of patients with hepatocellular carcinoma.

Authors:  Fengsui Chen; Jielong Wang; Shi'an Zhang; Mengxue Chen; Xia Zhang; Zhixian Wu
Journal:  J Cell Mol Med       Date:  2022-04-28       Impact factor: 5.295

4.  Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma.

Authors:  Wei Wei; Chao Liu; Meng Wang; Wei Jiang; Caihong Wang; Shuqun Zhang
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.